Key Takeaways: HRT is more effective than SSRIs for hot flashes — roughly 75% reduction versus 45-50%. But SSRIs have a legitimate role: women who cannot take HRT, women with significant depression beyond menopausal mood changes, and women on tamoxifen. Paroxetine 7.5 mg is the only FDA-approved SSRI for vasomotor symptoms. Venlafaxine performs similarly and has no tamoxifen interaction. The two can be combined safely in most cases. The wrong default is offering an SSRI instead of addressing hormones in a woman who could take HRT — a pattern still common in primary care.
The Question Behind the Protocol
Menopause and depression overlap. An estimated 20-30% of women develop new or worsened depressive symptoms in perimenopause, and another 30-40% report significant anxiety. These often appear alongside hot flashes, sleep disruption, and the full spectrum of vasomotor and cognitive symptoms.
When a woman presents with hot flashes, poor sleep, and low mood, she is often offered an SSRI. Sometimes that's the right call. Often it isn't — because the underlying driver is hormonal, and HRT treats both the mood component and the vasomotor symptoms more effectively.
This article compares efficacy, side effects, and use cases, and explains when to combine the two.
The Efficacy Data
For Hot Flashes
Treatment
Mean Reduction in Frequency
Typical Onset
Transdermal estradiol 0.05-0.1 mg
70-90%
2-4 weeks
Oral estradiol 0.5-1 mg
60-75%
2-4 weeks
Venlafaxine 75 mg
45-50%
2-4 weeks
Paroxetine 7.5 mg
35-45%
2-4 weeks
Escitalopram 10-20 mg
45-50%
2-4 weeks
Desvenlafaxine 100 mg
40-50%
2-4 weeks
Placebo
20-30%
—
The head-to-head MsFLASH trial compared low-dose oral estradiol (0.5 mg/day) with venlafaxine XR (75 mg/day) over 8 weeks in 339 symptomatic women [1]:
Estradiol reduced frequency by 52.9%
Venlafaxine by 47.6%
Placebo by 28.6%
The gap between HRT and SNRI was real but small. Both substantially outperformed placebo. The authors concluded that while estradiol is slightly more effective, the difference is not clinically dramatic — meaning SSRIs/SNRIs are a legitimate alternative for women who cannot or will not take hormones.
For Mood
The story differs by who you study:
In women without clinical depression but with perimenopausal mood symptoms: HRT often improves mood meaningfully, with effect sizes similar to SSRI treatment.
In women with established major depressive disorder during the transition: SSRIs remain first-line. HRT adds benefit in some studies but is not a reliable substitute.
In women with anxiety: Both help. Oral micronized progesterone (at bedtime) has mild anxiolytic effects via allopregnanolone that add to either approach.
A 2018 transdermal estradiol trial showed it prevented the development of clinically significant depressive symptoms in perimenopausal women — a preventive effect — but in women who already had MDD, SSRI-class treatment remained superior.
The Mechanistic Split
Hot flashes are driven by KNDy neurons in the hypothalamus, which become hyperactive when estrogen withdraws. There are two ways to quiet them:
Restore estrogen. Estradiol directly calms the KNDy signal.
Modulate serotonin/norepinephrine. SSRIs and SNRIs appear to work by stabilizing thermoregulatory tone through central serotonergic pathways — a separate route to the same physiologic endpoint.
This is why SSRIs work for hot flashes at doses lower than those needed for depression (paroxetine 7.5 mg vs 20-40 mg for MDD). The vasomotor effect uses different receptor dynamics than the antidepressant effect.
It also explains why combining the two can work — they operate on non-redundant systems.
Paroxetine 7.5 mg: The FDA-Approved Option
The only SSRI formally FDA-approved for menopausal vasomotor symptoms. Approved 2013 at a dose (7.5 mg) below the therapeutic range for depression.
Dose: 7.5 mg at bedtime.
Efficacy: In pivotal trials of 1,184 women, paroxetine 7.5 mg produced a median reduction of 5.6 moderate-to-severe hot flashes per day at 12 weeks, versus 3.9 for placebo — a 1.7 per day absolute advantage.
Side effects: Nausea, headache, fatigue early on. Much milder at 7.5 mg than at antidepressant doses.
Key drug interaction: Paroxetine is a strong CYP2D6 inhibitor. Tamoxifen requires CYP2D6 for activation to its active metabolite endoxifen. Co-administration reduces tamoxifen activation meaningfully, so paroxetine should be avoided in women on tamoxifen. Use venlafaxine or escitalopram instead.
Best candidate: Woman who cannot take HRT, wants the FDA-approved option, is not on tamoxifen.
Venlafaxine: The Most-Used Off-Label Option
An SNRI. Not FDA-approved for VMS but has the strongest evidence base of the off-label options.
Dose: 37.5 mg for the first week (to reduce nausea), then 75 mg daily.
Efficacy: 45-50% reduction in hot flash frequency in multiple trials. Nearly matched low-dose estradiol in the MsFLASH head-to-head [1].
Side effects: Nausea in the first 1-2 weeks. Can raise blood pressure mildly at higher doses. Discontinuation syndrome if stopped abruptly — must taper.
Key advantage: No significant CYP2D6 interaction. Safe with tamoxifen. This is why venlafaxine is often preferred in women with a history of breast cancer.
Best candidate: Breast cancer survivor on tamoxifen with vasomotor symptoms, or any woman who needs a non-hormonal option with robust evidence.
Other SSRIs and SNRIs
Escitalopram 10-20 mg: Effective for both hot flashes and mood. Cleaner side effect profile than paroxetine. Useful in women with significant depression plus VMS.
Desvenlafaxine 100 mg: Active metabolite of venlafaxine. Simpler pharmacokinetics, similar efficacy.
Citalopram 10-20 mg: Evidence is weaker than for escitalopram; often not first-choice.
Sertraline: Modest evidence for hot flashes. Better studied for depression.
Fluoxetine: Longer half-life, some evidence, but less consistent than SSRIs above.
The 2023 NAMS nonhormone therapy position statement gave SSRIs and SNRIs a Level I recommendation for VMS [2].
Women's HRT — Menopause-First Telehealth
Bioidentical estradiol, progesterone, and low-dose testosterone — all 50 states, unlimited physician access.
Absolute contraindication to HRT (active estrogen-sensitive cancer, recent VTE/stroke/MI, active liver disease)
Strong personal preference to avoid hormones after discussing options
Pre-existing major depression requiring pharmacotherapy regardless of menopausal status
On tamoxifen (choose venlafaxine or escitalopram, not paroxetine)
Cannot tolerate estrogen trial
Combine Both When
HRT alone does not fully control vasomotor symptoms despite adequate dosing
Co-existing MDD or severe anxiety that warrants pharmacotherapy
Mood and cognitive symptoms persist after 12 weeks of adequate HRT
Pre-existing SSRI-responsive mood disorder, now in menopausal transition
Most HRT-SSRI combinations are safe. The main exceptions:
Paroxetine + tamoxifen (avoid)
SSRI/SNRI + oral estrogen in women at VTE risk (transdermal estradiol preferred)
Watch for serotonin syndrome if combining multiple serotonergic agents (uncommon at standard doses)
Side Effect Comparison
HRT Side Effects
First 4-6 weeks: breast tenderness, mild fluid retention, spotting (especially if continuous combined regimen)
Persistent: generally well-tolerated; spotting resolves, breast tenderness subsides
Serious but rare: VTE (higher with oral than transdermal), endometrial hyperplasia (prevented by progestogen), small breast cancer signal with combined HRT beyond 5 years (magnitude is modest; see WHI-era data in context)
SSRI/SNRI Side Effects
First 2 weeks: nausea, headache, insomnia or sedation
Persistent: sexual side effects (30-50% of users — reduced libido, delayed orgasm, anorgasmia), emotional blunting, sleep changes, weight gain (SSRI-specific in some cases)
Discontinuation syndrome: dizziness, flu-like symptoms, "brain zaps" if stopped abruptly — especially venlafaxine and paroxetine (short half-lives). Must taper.
Serious but rare: serotonin syndrome (with polypharmacy), QT prolongation (citalopram at high doses)
The sexual side effects of SSRIs are under-discussed. For a woman who chose an SSRI partly for menopausal low libido, this trade-off matters.
A Practical Decision Tree
Step 1: Classify the primary complaint
If hot flashes/night sweats dominate → HRT unless contraindicated
If depression/anxiety dominate → consider SSRI as primary, HRT if vasomotor symptoms
If both are prominent → start with HRT, add SSRI at 12 weeks if mood not adequately addressed
Step 2: Check contraindications
Breast cancer history → avoid systemic HRT; consider venlafaxine, vaginal estrogen (low-dose) for GSM
Recent clot → avoid oral estrogen; transdermal may be acceptable after consultation
On tamoxifen → avoid paroxetine; use venlafaxine or escitalopram
Step 3: Optimize the first line
HRT: titrate over 6-8 weeks, aim for serum estradiol 50-80 pg/mL
SSRI: start low, uptitrate slowly if needed, reassess at 4-8 weeks
Step 4: Reassess at 12 weeks
If vasomotor symptoms persist on HRT: verify dose and absorption; consider dose increase
If mood symptoms persist on HRT: add SSRI
If hot flashes persist on SSRI: consider adding HRT (if eligible) or switching to fezolinetant
The Combination Protocol
For a woman with moderate hot flashes and moderate depression:
Add SSRI if mood not adequately addressed at 8-12 weeks: escitalopram 10 mg daily or venlafaxine 75 mg daily
Reassess at 16-20 weeks: most women are meaningfully better on the combination
Taper SSRI after 6-12 months of stability if appropriate; continue HRT as indicated
What About Testosterone?
Testosterone is not directly a menopause depression treatment, but it supports dopamine signaling, energy, and drive. Women with low libido, poor training response, or persistent low energy on optimized estradiol often benefit from adding low-dose transdermal testosterone (0.5-1 mg/day cream, targeting the upper female range).
Several products are marketed as "natural antidepressants" or "hormone-balancing" for menopausal mood. The evidence does not support them:
Black cohosh: Mixed evidence for hot flashes; no reliable effect on depression
St. John's wort: Drug-drug interactions, inconsistent quality, unclear effect size in perimenopause specifically
Wild yam cream: Does not convert to progesterone in humans
Evening primrose oil: No meaningful effect
"Bioidentical" compounded progesterone cream: Does not protect endometrium and absorption is inconsistent
These are not neutral alternatives. Choosing them over evidence-based therapy often means months of preventable symptoms.
Special Populations
Breast Cancer Survivors
Systemic HRT is generally avoided. The hot flash protocol:
Venlafaxine 75 mg or escitalopram 10-20 mg as first-line
Fezolinetant 45 mg if SSRI/SNRI insufficient and hot flashes are moderate-to-severe
Low-dose vaginal estrogen for GSM, after discussion with oncology
Avoid paroxetine on tamoxifen
Women with Cardiovascular Disease History
Transdermal estradiol is preferred if HRT is used
Avoid oral estrogen
SSRIs are generally safe; avoid citalopram at >20 mg (QT prolongation)
Venlafaxine can raise blood pressure — monitor
Women with Migraine with Aura
Oral estrogen may worsen migraine; transdermal estradiol is typically better tolerated
Continuous (non-cyclic) regimens reduce migraine frequency compared to cyclic
SSRIs are generally safe; avoid triptans with SSRIs at the same dose window (mild serotonin syndrome risk)
Surgically Menopausal Women
Women who have had bilateral oophorectomy enter an abrupt menopausal state. Symptoms are often severe and HRT is strongly indicated unless contraindicated. SSRIs alone are rarely sufficient.
Annual: breast exam, mammogram, endometrial assessment if bleeding
Serum estradiol target: 50-80 pg/mL for symptom control
SSRI Monitoring
Baseline: clinical mental health assessment, suicide risk screen (especially in women <25 or with prior history)
Week 2-4: side effect check, dose titration
Week 8-12: efficacy assessment
Periodic: blood pressure (venlafaxine, especially at higher doses), sodium (hyponatremia risk in elderly on SSRIs)
Finding a Provider
This decision — HRT, SSRI, or both — requires a provider comfortable with both domains. Many general practices default to SSRIs because they are familiar and have no monitoring burden. Many gynecology practices default to HRT or birth control pills without adequately assessing mood. A few midlife-focused clinics handle the integrated case well.
Look for a provider who:
Will order a full hormonal and metabolic workup before prescribing either
Discusses both HRT and SSRI options with their evidence base
Uses transdermal estradiol and micronized progesterone as defaults
Is comfortable prescribing both simultaneously when indicated
HRT outperforms SSRIs for hot flashes by roughly 25 percentage points in reduction. For women who can take it, HRT is the more effective primary treatment. For women who can't — breast cancer history, recent clot, strong preference to avoid hormones — SSRIs are a legitimate and evidence-backed alternative, with venlafaxine and paroxetine 7.5 mg as the strongest choices.
The wrong default, still common in primary care, is offering an SSRI first to a woman who could take HRT and wants effective vasomotor relief. The symmetric wrong default, less common but real, is refusing to consider SSRIs for a woman with significant depression that deserves direct treatment.
The best protocol for many women combines a low-dose transdermal HRT regimen with an SSRI — not because either alone is insufficient, but because they target non-overlapping pathways. Get the evaluation first, then pick the tool for the actual problem.
Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014;174(7):1058-66. PMID: 24861828
The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. PMID: 37252752
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. PMID: 36924778
Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008;15(2):310-8. PMID: 17917611
Santoro N. Perimenopause: from research to practice. J Womens Health (Larchmt). 2016;25(4):332-9. PMID: 26653408
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. PMID: 12117397
Frequently Asked Questions
Are SSRIs as effective as HRT for hot flashes?
No. HRT reduces hot flash frequency by roughly 70-90%, while SSRIs and SNRIs cluster at 40-60%. In the MsFLASH head-to-head trial, low-dose estradiol reduced hot flashes by 53% versus 48% for venlafaxine — a real but smaller difference. For women who can take HRT, it is the more effective choice. SSRIs are first-line when HRT is contraindicated.
What is the only FDA-approved SSRI for hot flashes?
Paroxetine 7.5 mg (low-dose, FDA-approved for VMS) is the only SSRI FDA-approved specifically for vasomotor symptoms associated with menopause. It was approved in 2013. Other SSRIs and SNRIs like venlafaxine, escitalopram, and desvenlafaxine are used off-label with evidence support but not formal FDA indication.
Should I take HRT or an SSRI for menopause depression?
It depends on your symptom profile. If hot flashes and vasomotor symptoms are prominent alongside low mood, HRT often resolves both. For women with moderate-to-severe depression, especially those with a history of MDD before menopause, an SSRI plus HRT or SSRI alone is appropriate. HRT is not a substitute for antidepressant treatment in established major depression.
Can I take HRT and an SSRI at the same time?
Yes, and many women do. The combination is safe and sometimes more effective than either alone. Avoid paroxetine if you are on tamoxifen, as it reduces tamoxifen activation via CYP2D6 inhibition. Venlafaxine, escitalopram, and desvenlafaxine do not have this interaction.
How quickly do SSRIs work for hot flashes?
Faster than they work for depression. Hot flash improvement typically begins within 2 weeks and peaks by 4-8 weeks. This is different from depression treatment, which often takes 4-6 weeks to show initial benefit. The hot flash effect appears to use a separate serotonergic mechanism from the antidepressant effect.
Who should choose an SSRI over HRT?
Women with a history of estrogen-sensitive breast cancer, recent VTE or stroke, active liver disease, or strong personal preference to avoid hormones. Women with prominent depression or anxiety alongside menopausal symptoms may benefit from an SSRI first, then adding HRT if vasomotor symptoms persist.
